KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Current Assets (2016 - 2025)

Acadia Pharmaceuticals has reported Current Assets over the past 16 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Current Assets at $1.1 billion for Q4 2025, up 13.19% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 13.19% YoY), and the annual figure for FY2025 was $1.1 billion, up 13.19%.
  • Current Assets for Q4 2025 was $1.1 billion at Acadia Pharmaceuticals, down from $1.1 billion in the prior quarter.
  • Over the last five years, Current Assets for ACAD hit a ceiling of $1.1 billion in Q3 2025 and a floor of $492.6 million in Q2 2023.
  • Median Current Assets over the past 5 years was $643.3 million (2021), compared with a mean of $694.7 million.
  • Biggest five-year swings in Current Assets: dropped 19.55% in 2022 and later soared 57.92% in 2024.
  • Acadia Pharmaceuticals' Current Assets stood at $617.8 million in 2021, then decreased by 17.79% to $507.9 million in 2022, then grew by 21.3% to $616.1 million in 2023, then surged by 52.29% to $938.3 million in 2024, then rose by 13.19% to $1.1 billion in 2025.
  • The last three reported values for Current Assets were $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $960.6 million (Q2 2025) per Business Quant data.